Andy Drechsler

Andy Drechsler joined Orcosa as Chief Financial Officer (CFO) in May 2026.  Andy offers 30 years of financial and operational leadership experience in life sciences companies.

Andy currently serves as acting CFO of Altesa BioSciences, a private clinical stage pharmaceutical focused on infectious diseases in respiratory diseases. From 2017 to 2021 Andy served as CFO of Provention Bio (now part of Sanofi), a biopharmaceutical company focused on intercepting and preventing autoimmune diseases like type one diabetes.  While at Provention, Andy helped grow the Company from 5 employees to over 80 employees, acquired three development stage programs, and raised over $300 million in equity capital.  Andy also served as CFO of Insmed (Nasdaq: INSM) from 2012 to 2017. While at Insmed, Andy helped raise over $400 million via the equity capital markets, helped grow the company from 40 to over 160 people, and established an international infrastructure of six entities operating in the US and the EU.  His prior CFO roles also include: VaxInnate Corporation and Valera Pharmaceuticals.  He also served as controller for Abbott Laboratories’ Point of Care Division (formerly i-STAT Corporation) and Biomatrix, Inc. (now part of Sanofi).

Andy graduated magna cum laude from Villanova University with a BS in Accounting and received his certified public accountant license in New Jersey.

Andy serves on the Board of Directors of Manasquan Bank and the NJ Chapter of Breakthrough Type One Diabetes.